Can you tell which patient has Folate MTHFR 677 C>T Polymorphism?

Without a genetic test, neither can we. However, it is well documented that 9% to 12% of the general population are TT homozygous affected. These patients lack the enzyme needed to metabolize folic acid. They get little folate activity from folic acid supplementation and remain at a higher estimated risk for NTDs and all folate related conditions.

Patients with MTHFR Polymorphism cannot fully metabolize folic acid to its active form

Another 44% of the general population are CT affected and cannot fully metabolize folic acid to its active form. These patients may or may not respond to the practice of folate loading (adding another 4mg on top of the PNV). These patients will receive the desired folate benefit from L-methylfolate and Néevo®. Néevo® contains L-methylfolate, the active form of folate, which bypasses the MTHFR polymorphism and meets the distinct nutritional needs of patients with the TT C677T genotype.

Genotype Mean RBC (µg/L)
TT 252 (202-317)
CT 321 (296-347)*
CC 347 (321-372)+
n=242 p<0.008 by ANOVA
* p<0.05 + p<0.005
  • In studies, the C667T alle polymorphism has been positively correlated with lower serum and red blood cell folate concentrations and an increase in the estimated risk of a neural tube defect.
  • In a recent study of pregnant women, over half were identified with the MTHFR C->T polymorphism.

Unlike folic acid, Néevo® is unaffected by the MTHFR C>T polymorphism.

Molloy Anne M, Daly Sean, Mills James L., Kirke Peaders N, Whitehead Alexander S, Ramsbottom Dorothy, Conley Mary R, Weir Donald G, and Scott John M: Thermolabile variant of 5,10-Methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. The Lancet 1997; Vol 349:1591-93

Néevo® caplets are a prescription medical food for the dietary management of those women under a physician's treatment for vitamin deficiency throughout pregnancy, postnatal and the lactating periods. Néevo® is specifically indicated for: patients with high risk pregnancies, older OB patients, and patients unable to fully metabolize folic acid.